- Lilly, with new data, to seek FDA approval of obesity drug retatrutide<figure><div><img src="https://imgproxy.divecdn.com/x5fF_ZCHHBjPFAGFuuKXSVkAgBGYTo2hZBIz9OcQdEo/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMDkyNDczMjEzLmpwZ…BioPharma Dive · 1d ago↗ source
- STAT+: What’s in the last-minute flurry of health care bills?Congress is scrambling to advance a slew of health care bills before an August recess. Price transparency and prior authorization top the list.STAT · 1d ago↗ source
- FDA panel confronting peptide controversyToday's biotech news features the FDA weighing the fate of peptides; approvals for RevMed, GSK; and data on Lilly's "triple-G."STAT · 1d ago